News and Trends 23 Oct 2018 Microbiome Biotech Enterome Signs Deal With Takeda Worth up to €600M The French biotech Enterome and Takeda are teaming up to fight Crohn’s disease, with a deal worth up to €600M. The two companies will collaborate in the development and commercialization of Enterome’s lead microbiome-targeting treatment currently in Phase I trials. Under the terms of the deal, Takeda will pay Enterome €44M upfront, and up to […] October 23, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Oct 2018 Innate’s Cancer Immunotherapy Combo Beats Standard Treatment Twofold A combination cancer immunotherapy from French biotech Innate Pharma was twice as effective at treating recurrent squamous cell carcinoma as standard therapy in a Phase II trial. Squamous cell carcinoma is a head and neck cancer that forms lesions in the mucous membranes of body cavities such as the mouth, nose and throat. “Patients are […] October 22, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2018 Spanish Biotech Partners Gilead to Develop Functional HIV Cure AELIX Therapeutics and Gilead will run a clinical trial testing a combination of treatments that has potential to let HIV-infected people ditch lifelong therapy. The trial, which will run in Spain, is planned to start in early 2019 and will recruit around 90 patients in the early stages of HIV infection. After receiving the […] October 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2018 Belgian Firm Will Develop Antibiotic Alternatives for Industrial Biotech Using CRISPR Syngulon will be developing antibacterial peptides using CRISPR/Cas9 gene editing technology thanks to an agreement with ERS Genomics, which licenses out CRISPR intellectual property in the EU. CRISPR technology is a hot topic in the biotech industry because it makes gene editing faster and easier than other techniques. This could make it very useful in […] October 17, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2018 Cancer Immunotherapy Biotech Raises €34M on Nasdaq Stockholm The Swedish biotech Immunicum has issued shares worth up to almost €34M on Nasdaq Stockholm, in an effort to accelerate the development of its cancer immunotherapy. Immunicum plans to use most of the funding to run a Phase Ib/II clinical trial that will test its lead cell therapy candidate in combination with checkpoint inhibitors to […] October 16, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 15 Oct 2018 Microsoft Signs its First Microbiome Partnership Microsoft Genomics will work with Cambridge-based Eagle Genomics to scale up its artificial intelligence platform for microbiome research. In recent years, it has become evident that the microbes that inhabit our body are key to our health. The microbiome has been linked to conditions such as diabetes, cancer, Alzheimer’s, multiple sclerosis and many more. However, large-scale studies […] October 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2018 Rechargeable Dentures Could Prevent Mouth Infections As well as helping you chew your hamburger, dentures could one day fight oral fungal infections, suggest researchers from Manchester Metropolitan University, UK. The population is getting older. In fact, it is predicted that almost half of Europe will be over 50 years old in the year 2050. Assuming that trends stay the same, this […] October 11, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2018 Cancer Immunotherapy Phase I on Hold After Patient Death The German biotech Affimed has halted two Phase I trials of its cancer immunotherapy after three patients suffered neurotoxicity due to the treatment, causing the death of one of them. Affimed was testing its immunotherapy AFM11 in 33 patients diagnosed with white blood cell cancer in two Phase I trials. One trial tested the therapy […] October 10, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Slow-Release Drug Biotech IPO Raises €30M The French biotech MedinCell, an injectable slow-release drug specialist, has received a shot of success as its IPO raises €30M in the Euronext stock exchange in Paris. MedinCell is hoping to improve patient compliance with medication regimes by injecting them with a drug-infused gel. Patient compliance with taking medication can be as low as 30% […] October 9, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Oct 2018 Hormone Therapy for Inherited Hormonal Disorder Fails at Phase III A European Phase III trial has become a major stress for British biotech Diurnal. Its specially designed hormone therapy was no better than conventional therapies in treating an inherited hormonal disorder. Congenital adrenal hyperplasia is a rare genetic condition where patients lack crucial enzymes for making hormones. The most common form lacks 21-hydroxylase, the enzyme […] October 9, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 8 Oct 2018 Oxford Biotech Launches with €26M to Target ‘Immunometabolism’ Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […] October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2018 Lab-Grown Antivenom Shows Potential for Curing Black Mamba Snakebite Antivenoms could one day be made in the lab instead of in animals. Researchers from the Technical University of Denmark have neutralized black mamba venom in mice with lab-grown human antibodies for the first time. Snakebite is a serious problem, causing the deaths of around 100,000 people every year, and about three times that number […] October 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email